NCT04145609

Brief Summary

Strategies to stop AKI-AKD-CKD continuum - Policy is one of the collaborative projects, Strategies to stop AKI-AKD-CKD continuum, Epidemiology, Immunology, Repair, Artificial intelligence, and Policy (EIRAP). It is aimed to study effective interventional strategies that lower the incidence of CKD among patients with AKD. The intensified AKD care to reduce CKD (ISACC trial) is a prospective, open-labeled, randomized controlled trial is designed to evaluate the efficacy of multidisciplinary team care (MDT) model and acute kidney disease (AKD) clinic visits

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
690

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2020

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 28, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 30, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

October 30, 2019

Status Verified

October 1, 2019

Enrollment Period

1 year

First QC Date

October 28, 2019

Last Update Submit

October 29, 2019

Conditions

Keywords

Acute Kidney InjuryAcute Kidney DiseaseChronic Kidney DiseaseAKIAKDCKDDecision Support Systems, ClinicalCDS

Outcome Measures

Primary Outcomes (1)

  • Proportion of Major adverse kidney event

    Proportion of MAKE * Renal progression to CKD * Chronic dialysis (any 1 outpatient dialysis after discharge) * Death

    90days

Secondary Outcomes (11)

  • Mortality

    30days, 60days, 90days, 180days, 360 days, 3years

  • Chronic dialysis

    90days, 180days, 360 days, 3years

  • Renal progression

    90days, 180days, 360 days, 3years

  • Time to MAKE

    90days, 180days, 1year (360days)

  • Time to death

    90days, 180days, 1year (360days)

  • +6 more secondary outcomes

Study Arms (2)

Intensified care

EXPERIMENTAL

Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic Participants randomized to this arm will receive multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist and dietitian. Besides intensified care, participants of this arm receive evaluation of biochemical and physiological renal function more frequently. In order to provide seamless care of this group, post-discharge acute kidney disease (AKD) clinic will also be arranged for them. Clinic visits consist of evaluation of renal function, reconciliation of medication and steering necessity of renal replacement therapy.

Behavioral: Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic

Usual care

NO INTERVENTION

No intervention: Usual care Participants randomized to this arm will receive usual care according to the medical decisions of principal care physician. Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patient will not have access to MDT care and AKD clinic.

Interventions

Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach

Intensified care

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 20 yrs
  • Severe AKD: Stage 2, Stage 3 and Dialysis-requiring AKD (AKD-D)

You may not qualify if:

  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA; Acute Disease Quality Initiative Workgroup 16.. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017 Apr;13(4):241-257. doi: 10.1038/nrneph.2017.2. Epub 2017 Feb 27.

    PMID: 28239173BACKGROUND
  • See EJ, Jayasinghe K, Glassford N, Bailey M, Johnson DW, Polkinghorne KR, Toussaint ND, Bellomo R. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019 Jan;95(1):160-172. doi: 10.1016/j.kint.2018.08.036. Epub 2018 Nov 23.

    PMID: 30473140BACKGROUND

MeSH Terms

Conditions

Acute Kidney InjuryRenal Insufficiency, Chronic

Interventions

Ambulatory Care Facilities

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Health FacilitiesHealth Care Facilities Workforce and Services

Study Officials

  • Mai-Szu Wu

    Shuang Ho Hospital, Taipei Medical University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Stop AKI-AKD-CKD continuum in Taiwan: from precision medicine to policy decision (EIRAP study)

Study Record Dates

First Submitted

October 28, 2019

First Posted

October 30, 2019

Study Start

January 1, 2020

Primary Completion

December 31, 2020

Study Completion

December 31, 2021

Last Updated

October 30, 2019

Record last verified: 2019-10